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Introduction {#sec004}
============

Heart failure (HF) has emerged as a major public health concern. In the United States, the prevalence of HF is 5.7 million people, and approximately 870,000 new cases are reported annually \[[@pone.0145514.ref001]\]. Although clinical trials have established numerous therapies for improving the clinical outcomes of patients with HF and reduced left ventricular (LV) ejection fraction (LVEF), the overall prognosis remains poor, with mortality exceeding 50% at 5 years with a high rate of rehospitalization (up to 50% in 1 y), placing a financial burden on national health care systems \[[@pone.0145514.ref002]--[@pone.0145514.ref005]\]. Using echocardiography to measure LVEF is noninvasive, and this technique is commonly performed to assess myocardial function for guiding clinical therapeutic strategy in patients with HF \[[@pone.0145514.ref006]\].

In patients with chronic systolic HF, LV function assessed using LVEF is a crucial determinant of cardiovascular outcomes \[[@pone.0145514.ref007],[@pone.0145514.ref008]\]. However, the precise association of LVEF with cardiovascular outcomes in patients with acute decompensated HF is controversial \[[@pone.0145514.ref009]\]. Because the LVEF measure is load-dependent and varies with hemodynamic status, it may underestimate or overestimate true myocardial function in various pathophysiologic conditions and precipitants of acute decompensation. A prospective study reported that LVEF was weakly correlated with hemodynamic measures and clinical outcomes in patients with acute HF \[[@pone.0145514.ref010]\]. In practice, myocardial recovery is possible, and thus significant LVEF changes occur after evidence-based HF therapy. Previous studies have not determined the exact relationship between baseline and posttreatment LVEF and cardiovascular outcomes, and the predictors of LV systolic function improvement remain elusive \[[@pone.0145514.ref011]--[@pone.0145514.ref017]\].

Therefore, this study evaluated the following: (1) the prognostic value of baseline LVEF in patients with ADHF compared with that of patients with LVEF 6 months posttreatment, (2) the prognostic value of the change in LVEF obtained from the difference between baseline and posttreatment LVEF, and (3) the predictors of patients with improved LVEF.

Methods {#sec005}
=======

Study Population and End Points {#sec006}
-------------------------------

The study conformed to the principles of the Declaration of Helsinki and was approved by Chang Gung Memorial Hospital Institutional Review Board. As written informed consent was not necessary and therefore not obtained for review of medical records, the patient records and information were anonymized and deidentified prior to analysis

In Protocol 1, 811 consecutive patients admitted to our hospital from January to December 2010 with a principal diagnosis of ADHF and baseline echocardiographic LVEF ≤35% were enrolled. For each admission, the presence of ADHF was confirmed by 2 authors (Yuan-Chuan Hsiao and Cian-Ruei Jian), who followed the Framingham criteria, reviewed all patient charts independently, and reached a consensus on each case. All patients were treated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs), aldosterone antagonists, and β blockers if there was no contraindication, and these medications were continued and up-titrated during follow-up visits. For patients with de novo HF, detailed clinical information acquirement, laboratory studies, electrocardiography (ECG), echocardiography, nuclear myocardial perfusion scanning, cardiac magnetic resonance imaging, and/or coronary angiography were implemented to maximize HF etiology precision. In addition, causes and precipitants for ADHF were identified, and treatment with corresponsive therapies according to the contemporary HF guidelines \[[@pone.0145514.ref006]\] was applied, including coronary revascularization for ischemic heart disease (IHD), valvular surgery for severe symptomatic valvular heart disease, radiofrequency ablation for tachyarrhythmia, and device implantation for bradycardia therapy, cardiac resynchronized therapy, and/or sudden death prevention. The primary and secondary end points were defined as all-cause mortality and HF readmission. Medical records were reviewed for each patient after enrollment and were searched to identify deaths and subsequent admission with a principal diagnosis of congestive HF; these outcomes were confirmed during regular visits and telephone contact with the patients or their relatives through Dec. 31, 2013. Patients with survival \<6 months, loss to follow-up, or unavailable posttreatment LVEF data were excluded. The prognostic values of baseline and posttreatment LVEF for the study end points were compared. In Protocol 2, according to the change in LVEF, the patients were separated into 3 groups: improved LVEF (change of LVEF: ≥+10%), unchanged LVEF (change of LVEF: --10% to +10%), and reduced LVEF (change of LVEF: ≤--10%). The prognostic value of improved LVEF end points was assessed. In Protocol 3, independent variables that were associated with improved LVEF were evaluated.

Data Collection and Variables {#sec007}
-----------------------------

Data recorded on the abstraction form included clinical symptoms, New York Heart Association functional class (NYHA Fc), comorbidities, laboratory data, admission blood pressure and heart rate, discharge medications, and 12-lead ECG results. The recorded comorbidities were hypertension (HT), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), stroke, cirrhosis, and end-stage renal disease (ESRD). Specifically, ESRD was defined as estimated GFR \<15 mL/min/1.73m^2^ with long-term dialysis therapy. IHD was defined as history of myocardial infarction or angina with documented myocardial ischemia identified using stress tests, a pathologic Q wave on an ECG, or significant \>50% stenosis in one or more coronary arteries on a coronary angiogram. Baseline echocardiography evaluations were conducted at admission, and LVEF was measured using the M-mode or modified Simpson's method, as recommended by the American Society of Echocardiography \[[@pone.0145514.ref018]\]. Posttreatment LVEF was defined as echocardiographic assessment of at least 6 months after enrollment.

Statistical Analysis {#sec008}
--------------------

The chi-square test or Fisher's exact test was used to evaluate dichotomous variables, and the Student *t* test was used for continuous variables. We analyzed the association of candidate variables with all-cause mortality and HF readmission in a univariate Cox proportional hazards regression model and assessed the predictive value of baseline LVEF, posttreatment LVEF, and improved LVEF \>10% after adjusting for baseline clinical characteristics. The patients were divided into 3 groups according to baseline or posttreatment LVEF tertiles. Kaplan--Meier curves with log-rank tests were used to construct cumulative survival of all-cause mortality and HF readmission rates for estimating the differences among the 3 groups. Variables that differed significantly among the improved, unchanged, or reduced LVEF groups were analyzed using a multivariate logistic regression model to identify the independent predictors of improved LVEF. The differences in all-cause mortality and HF readmission among the improved, unchanged, and reduced LVEF groups were also depicted using Kaplan--Meier curves with log-rank tests. A *P* value below .05 indicated statistical significance. Two-tailed analysis was applicable to all variable assessments. Statistical analysis was performed using SPSS 18.0 (SPSS Inc., Chicago, IL). Incremental values of baseline LVEF, posttreatment LVEF, and LVEF changes were assessed in 3 modeling steps by using nested regression models. The first step consisted of fitting a multivariate base model of age, sex, HT, DM, IHD, COPD, ESRD, and NYHA Fc. Either baseline LVEF, posttreatment LVEF, or LVEF change was included in the second step. The change in overall log likelihood ratio χ^2^ was used to assess the increase in predictive power after adding LVEF.

Results {#sec009}
=======

Protocol 1: Outcomes and Predictors of Baseline LVEF and Posttreatment LVEF {#sec010}
---------------------------------------------------------------------------

Of the 811 patients with ADHF that we initially enrolled, we excluded 171 who survived for less than 6 months after enrollment, 26 patients who were lost to follow-up, and 186 patients for whom 6-month posttreatment echocardiography data were unavailable. The final study population consisted of 428 patients (mean age: 64 ± 15 y), 304 of whom were male ([Fig 1](#pone.0145514.g001){ref-type="fig"}). Baseline characteristics are provided in [Table 1](#pone.0145514.t001){ref-type="table"}. In the follow-up period (mean: 34.7 ± 10 mo), 86 cases of all-cause mortality (20.1%) and 240 HF readmissions (56.1%) were recorded. Tables [2](#pone.0145514.t002){ref-type="table"} and [3](#pone.0145514.t003){ref-type="table"} present the baseline characteristics of the all-cause mortality and HF readmission groups, respectively. The patients who died tended to be older, to have been treated with diuretics, and to have more severe HF symptoms (NYHA function class III/IV), COPD, conduction disturbance QRS duration \>120 ms, lower posttreatment LVEF, and higher serum creatinine levels.

![Flow chart of patient enrollment and study eligibility.](pone.0145514.g001){#pone.0145514.g001}

10.1371/journal.pone.0145514.t001

###### Baseline characteristics of study population (*n* = 428).

![](pone.0145514.t001){#pone.0145514.t001g}

  Characteristics          All patient[\*](#t001fn001){ref-type="table-fn"}
  ------------------------ --------------------------------------------------
  Gender (male)            304 (71.0%)
  Age (year)               64±15
  NYHA Fc III/IV           230 (53.7%)
  Comorbidity              
   IHD                     181 (42.3%)
   HT                      224 (52.3%)
   DM                      132 (30.8%)
   Stroke                  49 (11.4%)
   COPD                    55 (12.9%)
   ESRD                    22 (5.1%)
   Liver cirrhosis         15 (3.5%)
  Laboratory data          
   Hemoglobin (g/dL)       12.7±2.3
   BUN (mg/dL)             28.1±18.4
   Creatinine (mg/dL)      1.67±1.87
   Albumin (g/dL)          3.7±0.5
   Sodium (mEq/L)          139.2±3.7
   Uric acid (mg/dL)       7.7±2.4
  Admission vital signs    
   SBP (mmHg)              126±22
   DBP (mmHg)              74±15
   Heart rate (bpm)        86±20
  Echo parameters          
   LA diameter (mm)        45.1±8.5
   LVEDD (mm)              61.2±8.7
   Baseline LVEF %         26.9±6.1
   Post-treatment LVEF%    35.1±14.1
  ECG characteristics      
   Atrial fibrillation     58 (13.6%)
   QRS duration \>120 ms   138 (32.2%)
   Complete LBBB           41 (9.6%)
  Medications              
   Warfarin                50 (11.7%)
   Aspirin                 182 (42.5%)
   Clopidogrel             66 (15.4%)
   ACEI or ARB             319 (74.5%)
   Beta blocker            298 (69.6%)
   Digoxin                 105 (24.5%)
   Diuretics               314 (73.4%)
  Device therapy           
   PPM                     22 (5.1%)
   ICD                     14 (3.3%)
   CRT                     28 (6.5%)
   CRT-D                   33 (7.7%)

\*Categorical variables are expressed in number and percentage; continuous variables are presented as mean ± standard deviation.

ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy-defibrillator; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; HT, hypertension; ICD, implantable cardioverter defibrillator; IHD, ischemic heart disease; LBBB, left bundle-branch block; LA, left atrial; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class; PPM, permanent pacemaker; SBP, systolic blood pressure.

10.1371/journal.pone.0145514.t002

###### Baseline characteristics stratified by all-cause mortality.

![](pone.0145514.t002){#pone.0145514.t002g}

  Characteristics            Mortality (*n* = 86)   Survival (*n* = 342)   *P*
  -------------------------- ---------------------- ---------------------- -------
  Gender (male)              62 (72.1)              242 (70.8)             0.894
  Age (year)                 70±14                  62±15                  0.000
  NYHA Fc III/IV             56 (65.1)              174 (50.9)             0.021
  Comorbidity                                                              
   HT                        51 (59.3)              173 (50.6)             0.184
   DM                        32 (37.2)              100 (29.2)             0.154
   IHD                       37 (43.0)              144 (42.1)             0.903
   Stroke                    14 (16.3)              35 (10.2)              0.130
   COPD                      18 (20.9)              37 (10.8)              0.018
   ESRD                      8 (9.3)                14 (4.1)               0.059
   Liver cirrhosis           6 (7.0)                9 (2.6)                0.091
  Biochemistry                                                             
   Cr (mg/dL)                2.16±2.0               1.51±1.7               0.012
   Sodium (mEq/L)            139±3.7                139±3.8                0.502
  Admission vital signs                                                    
   SBP (mmHg)                124±24                 127±21                 0.311
   DBP (mmHg)                71±16                  74±15                  0.112
   Heart rate (bpm)          86±21                  86±19                  0.909
  Echo findings                                                            
   LA diameter (mm)          45.6±8.4               44.9±8.6               0.546
   LVEDD (mm)                61.7±8.9               61.1±8.7               0.534
   Baseline LVEF (%)         26.6±6.0               26.9±6.9               0.226
   Post treatment LVEF (%)   30.3±10.7              36.3±14.6              0.000
  ECG characteristics                                                      
   AF                        12 (14.0)              46 (13.5)              0.862
   QRS \>120ms               34 (42.0)              104 (33.1)             0.151
  Medication                                                               
   Aspirin                   31 (36.0)              151 (44.2)             0.182
   Clopidogrel               16 (18.6)              50 (14.6)              0.403
   ACEI or ARB               64 (74.4)              255 (74.6)             1.000
   Beta blocker              58 (67.4)              240 (70.2)             0.694
   Digoxin                   16 (18.6)              89 (26.0)              0.164
   Diuretics                 73 (84.9)              241 (70.5)             0.006
   Amiodarone                8 (9.3)                40 (11.7)              0.702
   Aldosterone antagonist    21 (24.4)              94 (27.5)              0.683
   CCB                       6 (7.0)                39 (11.4)              0.325
   Statin                    29 (33.7)              155 (45.3)             0.067

10.1371/journal.pone.0145514.t003

###### Baseline characteristics stratified by HF readmission.

![](pone.0145514.t003){#pone.0145514.t003g}

  Characteristics            No (*n* = 188)   Readmission (*n* = 240)   *P*
  -------------------------- ---------------- ------------------------- -------
  Gender (male)              143 (76.1)       161 (67.1)                0.053
  Age (year)                 61±16            66±14                     0.001
  NYHA class III/IV          88 (46.8)        142 (59.2)                0.011
  Comorbidity                                                           
   HT                        76 (40.4)        148 (61.7)                0.000
   DM                        46 (24.5)        86 (35.8)                 0.012
   IHD                       84 (44.7)        97 (40.4)                 0.377
   Stroke                    23 (12.2)        26 (10.8)                 0.650
   COPD                      13 (6.9)         47 (17.5)                 0.001
   ESRD                      5 (2.7)          17 (7.1)                  0.047
   Liver cirrhosis           7 (3.7)          8 (3.3)                   0.091
  Biochemistry                                                          
   Cr (mg/dL)                1.41±1.4         1.87±2.0                  0.008
   Sodium (mEq/L)            139±3.6          139±3.8                   0.970
  Admission vital signs                                                 
   SBP (mmHg)                126±23           126±21                    0.858
   DBP (mmHg)                74±15            74±15                     0.943
   Heart rate (bpm)          85±20            87±20                     0.342
  Echo findings                                                         
   LA diameter (mm)          43.6±9.0         46.2±8.0                  0.001
   LVEDD (mm)                60.9±8.7         61.4±8.8                  0.476
   Baseline LVEF (%)         27.3±5.7         26.5±6.5                  0.196
   Post treatment LVEF (%)   38.0±14.6        32.8±13.4                 0.000
  ECG characteristics                                                   
   AF                        22 (11.7)        36 (15.0)                 0.393
   QRS \>120ms               51 (30.9)        87 (37.8)                 0.165
  Medication                                                            
   Aspirin                   80 (42.6)        102 (42.5)                1.000
   Clopidogrel               24 (12.8)        42 (17.5)                 0.225
   ACEI or ARB               139 (73.9)       180 (75.0)                0.824
   Beta blocker              129 (68.6)       169 (70.4)                0.751
   Digoxin                   46 (24.5)        59 (24.6)                 1.000
   Diuretics                 129 (68.6)       185 (77.1)                0.061
   Amiodarone                21 (11.2)        27 (11.3)                 1.000
   Aldosterone antagonist    46 (24.5)        69 (28.8)                 0.380
   CCB                       18 (9.6)         27 (11.3)                 0.636
   Statin                    76 (40.4)        108 (45.0)                0.376

ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; HT, hypertension; IHD, ischemic heart disease; LBBB, left bundle-branch block; LA, left atrial; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class; SBP, systolic blood pressure.

We divided the patients with HF by baseline LVEF and posttreatment LVEF into tertiles and compared them using Kaplan--Meier analysis. The difference between the posttreatment LVEF tertiles for future events was statistically significant (*P* = .01 for all-cause mortality, *P* \< .001 for HF readmission), but that between the baseline LVEF tertiles was not (*P* = .52 for all-cause mortality, *P* = .69 for HF readmission) (Figs [2A, 2B](#pone.0145514.g002){ref-type="fig"} and [3A, 3B](#pone.0145514.g003){ref-type="fig"}). In the univariate Cox proportional hazards model, 4 parameters were predictive of all-cause mortality: age, COPD, NYHA Fc III/IV, and posttreatment LVEF. The risk of all-cause mortality increased significantly with age (hazard ratio \[HR\] = 1.04, *P* \< .001), COPD (HR = 1.89, *P* = .028), NYHA Fc III/IV (HR = 1.93, *P* = .004), posttreatment LVEF (HR = 0.68, *P* = .005) ([Table 4](#pone.0145514.t004){ref-type="table"}). In the univariate Cox proportional hazards model, 8 parameters were predictive of HF readmission: age, male sex, HT, DM, COPD, ESRD, NYHA Fc III/IV, and posttreatment EF. However, regardless of all-cause mortality or HF readmission, baseline LVEF did not have a predictive value. In the multivariate Cox proportional hazards model, after adjustment for age, sex, HF, DM, IHD, COPD, ESRD, and NYHA Fc III/IV, posttreatment LVEF remained a statistically significant predictor of future events (HR = 0.39, *P* \< .001 for all-cause mortality; HR 0.67, *P* \< .001 for HF readmission), but not baseline LVEF (*P* = .17 for all-cause mortality, *P* = .99 for HF readmission) ([Table 4](#pone.0145514.t004){ref-type="table"}; Models 1 and 2).

![Cumulative percent survival free of all-cause mortality according to baseline LVEF (A), posttreatment LVEF (B), and LVEF change (C).\
The Kaplan--Meier survival analyses for the patients with HF divided into tertiles by posttreatment LVEF or LVEF change reveal significant differences between the groups in all-cause mortality (*P* = .01). However, all-cause mortality does not differ significantly between the groups according to the baseline LVEF tertiles.](pone.0145514.g002){#pone.0145514.g002}

![Cumulative percent survival free of HF readmission according to baseline LVEF (A), posttreatment LVEF (B), and LVEF change (C).\
The Kaplan--Meier survival analyses for the patients with HF divided into tertiles by posttreatment LVEF or LVEF change reveal significant differences between the groups in HF readmission (*P* \< .001). However, HF readmission does not differ significantly between the groups according to the baseline LVEF tertiles.](pone.0145514.g003){#pone.0145514.g003}

10.1371/journal.pone.0145514.t004

###### Predictors of all-cause mortality and heart failure readmission.

![](pone.0145514.t004){#pone.0145514.t004g}

  --------------------- --------------------- ----------------------------------------------- ------------------- ----------------------------------------------- ------------------- ----------------------------------------------- ------------------- -----------------------------------------------
  All-Cause Mortality   Univariate Analysis   Multivariate Analysis                                                                                                                                                                                       
                                              Model 1                                         Model 2             Model 3                                                                                                                                 
                        HR (95% CI)           *P*                                             HR (95% CI)         *P*                                             HR (95% CI)         *P*                                             HR (95% CI)         *P*
  Age                   1.04 (1.03--1.06)     \<0.0001[\*](#t004fn001){ref-type="table-fn"}   1.05 (1.03--1.07)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}   1.05 (1.03--1.07)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}   1.04 (1.03--1.07)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}
  Sex                   1.07 (0.67--1.77)     0.7775                                          1.26 (0.78--2.11)   0.3430                                          1.20 (0.74--2.01)   0.4590                                          1.27 (0.79--2.12)   0.3293
  HT                    1.34 (0.87--2.08)     0.1858                                          1.02 (0.65--1.62)   0.9326                                          1.06 (0.68--1.68)   0.8013                                          1.08 (0.69--1.71)   0.7333
  DM                    1.41 (0.90--2.17)     0.1345                                          1.45 (0.89--2.32)   0.1303                                          1.45 (0.89--2.33)   0.1325                                          1.44 (0.89--2.29)   0.1395
  IHD                   1.01 (0.65--1.55)     0.9649                                          0.71 (0.45--1.12)   0.1410                                          0.74 (0.47--1.15)   0.1746                                          0.75 (0.48--1.17)   0.2121
  COPD                  1.89 (1.07--3.14)     0.0284[\*](#t004fn001){ref-type="table-fn"}     1.22 (0.67--2.09)   0.5032                                          1.28 (0.71--2.17)   0.3984                                          1.39 (0.77--2.36)   0.2603
  ESRD                  2.20 (0.97--4.28)     0.0568                                          3.38 (1.45--6.92)   0.0066[\*](#t004fn001){ref-type="table-fn"}     3.31 (1.42--6.80)   0.0076[\*](#t004fn001){ref-type="table-fn"}     3.12 (1.34--6.40)   0.0107[\*](#t004fn001){ref-type="table-fn"}
  NHYA Fc               1.93 (1.23--3.07)     0.0036[\*](#t004fn001){ref-type="table-fn"}     1.61 (1.02--2.59)   0.0402[\*](#t004fn001){ref-type="table-fn"}     1.80 (1.14--2.90)   0.0110                                          1.83 (1.16--2.96)   0.0090[\*](#t004fn001){ref-type="table-fn"}
  Baseline LVEF         0.86 (0.66--1.12)     0.2672                                          0.83 (0.63--1.09)   0.1740                                                                                                                                  
  Post-Treatment LVEF   0.68 (0.52--0.89)     0.0051[\*](#t004fn001){ref-type="table-fn"}                                                                         0.39 (0.22--0.67)   0.0008[\*](#t004fn001){ref-type="table-fn"}                         
  Change of LVEF        0.63 (0.45--0.88)     0.0077[\*](#t004fn001){ref-type="table-fn"}                                                                                                                                             0.59 (0.42--0.83)   0.0026[\*](#t004fn001){ref-type="table-fn"}
  HF Re-Admission       Univariate Analysis   Multivariate Analysis                                                                                                                                                                                       
                                              Model 1                                         Model 2             Model 3                                                                                                                                 
                        HR (95% CI)           *P*                                             HR (95% CI)         *P*                                             HR (95% CI)         *P*                                             HR (95% CI)         *P*
  Age                   1.02 (1.00--1.03)     \<0.0001[\*](#t004fn001){ref-type="table-fn"}   1.01 (1.01--1.02)   0.0022[\*](#t004fn001){ref-type="table-fn"}     1.02 (1.01--1.03)   0.0012[\*](#t004fn001){ref-type="table-fn"}     1.01 (1.00--1.02)   0.0030[\*](#t004fn001){ref-type="table-fn"}
  Sex                   0.72 (0.55--0.95)     0.0191                                          0.83 (0.62--1.10)   0.1849                                          0.75 (0.57--1.00)   0.0489[\*](#t004fn001){ref-type="table-fn"}     0.78 (0.59--1.04)   0.0884
  HT                    1.77 (1.36--2.30)     \<0.0001[\*](#t004fn001){ref-type="table-fn"}   1.62 (1.23--2.14)   0.0005[\*](#t004fn001){ref-type="table-fn"}     1.67 (1.28--2.21)   0.0002[\*](#t004fn001){ref-type="table-fn"}     1.72 (1.31--2.26)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}
  DM                    1.47 (1.12--1.90)     0.0055[\*](#t004fn001){ref-type="table-fn"}     1.30 (0.98--1.72)   0.0686                                          1.26 (0.95--1.66)   0.1090                                          1.26 (0.95--1.66)   0.1031
  IHD                   0.88 (0.68--1.13)     0.3151                                          0.74 (0.56--0.97)   0.0274[\*](#t004fn001){ref-type="table-fn"}     0.72 (0.55--0.95)   0.0173[\*](#t004fn001){ref-type="table-fn"}     0.72 (0.55--0.95)   0.0187[\*](#t004fn001){ref-type="table-fn"}
  COPD                  1.90 (1.34--2.62)     0.0005[\*](#t004fn001){ref-type="table-fn"}     1.59 (1.10--2.25)   0.0137[\*](#t004fn001){ref-type="table-fn"}     1.66 (1.15--2.32)   0.0071[\*](#t004fn001){ref-type="table-fn"}     1.77 (1.24--2.48)   0.0023[\*](#t004fn001){ref-type="table-fn"}
  ESRD                  2.00 (1.17--3.17)     0.0129[\*](#t004fn001){ref-type="table-fn"}     1.91 (1.11--3.10)   0.0220[\*](#t004fn001){ref-type="table-fn"}     2.14 (1.24--3.49)   0.0081[\*](#t004fn001){ref-type="table-fn"}     2.05 (1.19--3.32)   0.0117[\*](#t004fn001){ref-type="table-fn"}
  NHYA Fc               1.52 (1.17--1.97)     0.0014[\*](#t004fn001){ref-type="table-fn"}     1.40 (1.08--1.83)   0.0123[\*](#t004fn001){ref-type="table-fn"}     1.49 (1.15--1.95)   0.0029[\*](#t004fn001){ref-type="table-fn"}     1.49 (1.15--1.95)   0.0028[\*](#t004fn001){ref-type="table-fn"}
  Baseline LVEF         0.97 (0.83--1.14)     0.7258                                          1.00 (0.85--1.17)   0.9961                                                                                                                                  
  Post-Treatment LVEF   0.74 (0.63--0.87)     0.0003[\*](#t004fn001){ref-type="table-fn"}                                                                         0.67 (0.57--0.79)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}                       
  Change of LVEF        0.68 (0.56--0.84)     0.0003[\*](#t004fn001){ref-type="table-fn"}                                                                                                                                             0.61 (0.49--0.74)   \<0.0001[\*](#t004fn001){ref-type="table-fn"}
  --------------------- --------------------- ----------------------------------------------- ------------------- ----------------------------------------------- ------------------- ----------------------------------------------- ------------------- -----------------------------------------------

\*Denotes *P* \< .05.

CI, confidence interval; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; DM, diabetes mellitus; HR, hazard ratio; HT, hypertension; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class.

Protocols 2 and 3: Outcomes and Predictors of LVEF Change 6 Months Posttreatment {#sec011}
--------------------------------------------------------------------------------

Of the study patients, improved LVEF was noted in 172 (40.1%), with LVEF increasing from 26.0% ± 6.5% to 47.6% ± 12.2%. [Table 5](#pone.0145514.t005){ref-type="table"} presents the baseline characteristics of the patients stratified into improved, unchanged, or reduced LVEF groups. The patients with improved LVEF were more likely to have NYHA class III/IV (*P* = .03), higher systolic or diastolic blood pressure (*P* = .05/.02), QRS \> 120 ms (*P* = .04), and a smaller LV end diastolic diameter (LVEDD) (*P* \< .001). The improved LVEF group had a markedly lower all-cause mortality rate than the other 2 groups did (13.4% vs 23.9% and 29.4%, respectively); and a lower HF readmission rate (48.3% vs 57.7% and 85.3%, respectively). According to the Kaplan--Meier survival analyses, the difference among the improved, unchanged, and reduced LVEF groups (*P* = .02 for all-cause mortality and *P* \< .001 for HF readmission) (Figs [2C](#pone.0145514.g002){ref-type="fig"} and [3C](#pone.0145514.g003){ref-type="fig"}) was significant; the patients with improved LVEF had a superior prognosis compared with those with unchanged or reduced LVEF). According to a multivariate Cox proportional hazards model, after adjustment for age, sex, HF, DM, IHD, COPD, ESRD, and NYHA Fc III/IV, posttreatment LVEF remained a statistically significant predictor of future events (HR = 0.59, *P* = .003 for all-cause mortality; HR = 0.61, *P* \< .001 for HF readmission). After a multivariate logistic regression with the same adjustments, only LVEDD was an independent predictor of LVEF improvement after 6 months (Odds ratio \[OR\] = 0.94, *P* \< .001) ([Table 6](#pone.0145514.t006){ref-type="table"}).

10.1371/journal.pone.0145514.t005

###### Baseline characteristics stratified into improved, unchanged, and reduced LVEF groups.

![](pone.0145514.t005){#pone.0145514.t005g}

  Characteristics           Improved (n = 172)   Unchanged (*n* = 222)   Worsened (n = 34)   *P*
  ------------------------- -------------------- ----------------------- ------------------- --------------------------------------------
  Gender (male)             116 (67.4)           160 (72.1)              28 (82.4)           0.191
  Age (year)                64±15                64±15                   65±12               0.731
  NYHA class III/IV         106 (61.6)           108 (48.6)              16 (47.1)           0.027[\*](#t005fn001){ref-type="table-fn"}
  Comorbidity                                                                                
   HT                       93 (54.1)            111 (50.0))             20 (58.8)           0.531
   DM                       52 (30.2)            66 (29.7)               14 (41.2)           0.394
   IHD                      72 (41.9)            92 (41.4)               17 (50.0)           0.636
   Previous stroke          19 (38.8)            24 (10.8)               6 (7.6)             0.495
   COPD                     24 (14.0)            28 (12.6)               3 (8.8)             0.708
   ESRD                     11 (6.4)             9 (4.1)                 2 (5.9)             0.568
   Liver cirrhosis          5 (2.9)              9 (4.1)                 1 (2.9)             0.814
  Biochemistry                                                                               
   Cr (mg/dL)               1.61±1.6             1.71±2.0                1.62±1.1            0.832
   Sodium (mEq/L)           139±3.7              140±3.6                 138±4.4             0.121
  Vital signs                                                                                
   SBP (mmHg)               129±23               125±21                  120±22              0.046[\*](#t005fn001){ref-type="table-fn"}
   DBP (mmHg)               76±17                73±15                   69±13               0.016[\*](#t005fn001){ref-type="table-fn"}
   Heart rate (bpm)         89±23                84±16                   87±18               0.291
  Echo findings                                                                              
   LA diameter (mm)         44.4±8.8             45.2±8.6                47.3±6.3            0.172
   LVEDD (mm)               58.3±8.4             63.0±8.6                63.3±7.4            0.000[\*](#t005fn001){ref-type="table-fn"}
   Baseline LVEF %          26.0+6.5             26.9±5.9                30.8±3.7            
   Second LVEF %            47.6±12.2            28.1±7.1                17.4±3.2            
  ECG characteristics                                                                        
   AF                       30 (17.4)            23 (10.4)               5 (14.7)            0.123
   QRS duration \>120 ms    44 (27.8)            80 (38.6)               14 (46.7)           0.038[\*](#t005fn001){ref-type="table-fn"}
  Medication                                                                                 
   Aspirin                  74 (43.0)            99 (44.6)               9 (26.5)            0.136
   Clopidogrel              34 (19.8)            25 (11.3)               7 (20.6)            0.047[\*](#t005fn001){ref-type="table-fn"}
   ACEI or ARB              131 (76.2)           167 (75.2)              21 (61.8)           0.200
   Beta blocker             121 (70.3)           149 (67.1)              28 (82.4)           0.191
   Digoxin                  45 (26.2)            58 (26.1)               13 (12.4)           0.053
   Diuretics                128 (74.4)           162 (73.0)              24 (70.6)           0.883
   Amiodarone               22 (12.8)            24 (10.8)               2 (5.9)             0.488
   Aldosterone antagonist   43 (25.0)            62 (27.9)               10 (29.4)           0.762
  All-cause mortality       23 (13.4)            53 (23.9)               10 (29.4)           0.025[\*](#t005fn001){ref-type="table-fn"}
  HF readmission            83 (48.3)            128 (57.7)              29 (85.3)           0.000[\*](#t005fn001){ref-type="table-fn"}

\*Denotes significance at the *P* \< .05 level.

ACEI, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy-defibrillator; DBP, diastolic blood pressure; DM, diabetes mellitus; ESRD, end-stage renal disease; HT, hypertension; ICD, implantable cardioverter defibrillator; IHD, ischemic heart disease; LBBB, left bundle-branch block; LA, left atrial; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class; PPM, permanent pacemaker; SBP, systolic blood pressure.

10.1371/journal.pone.0145514.t006

###### Predictors of improved LVEF after standard HF treatment according to logistic regression analysis.
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  Variable                 Univariate OR (95% CI)   *P*                                          Multivariate OR (95% CI)   *P*
  ------------------------ ------------------------ -------------------------------------------- -------------------------- --------------------------------------------
  Age, per year            1.00 (0.99--1.01)        0.860                                                                   
  NYHA Fc III/IV           1.71 (1.15--2.53)        0.007[\*](#t006fn001){ref-type="table-fn"}   1.35 (0.87--2.10)          0.188
  IHD                      0.97 (0.66--1.44)        0.883                                                                   
  AF                       1.72 (0.99--3.00)        0.056                                        1.35 (0.74--2.46)          0.334
  QRS\>120ms               0.59 (0.38--0.91)        0.016[\*](#t006fn001){ref-type="table-fn"}   0.78 (0.49--1.24)          0.287
  LVEDD, per mm            0.93 (0.91--0.96)        0.000[\*](#t006fn001){ref-type="table-fn"}   0.94 (0.91--0.96)          0.000[\*](#t006fn001){ref-type="table-fn"}
  SBP, per mmhg            1.01 (1.00--1.02)        0.038[\*](#t006fn001){ref-type="table-fn"}                              
  DBP, per mmhg            1.02 (1.00--1.03)        0.012[\*](#t006fn001){ref-type="table-fn"}   1.01 (0.99--1.01)          0.748
  HR, per bpm              1.01 (1.00--1.02)        0.019[\*](#t006fn001){ref-type="table-fn"}                              
  Beta blocker             1.06 (0.70--1.61)        0.790                                                                   
  ACEi or ARB              1.16 (0.74--1.81)        0.526                                                                   
  Aldosterone antagonist   0.85 (0.55--1.32)        0.475                                                                   

\*Denotes significance at the *P* \< .05 level.

The nested regression model results and Harrell's C statistic indicated that adding posttreatment LVEF to base model yielded a slight increase in predictive power for all-cause mortality (*P* \< .001) but that adding baseline LVEF did not ([Fig 4A](#pone.0145514.g004){ref-type="fig"}). Similarly, for predicting HF readmission, adding posttreatment LVEF resulted in an incremental increase in predictive power over the base model (*P* \< .001), but adding baseline LVEF did not ([Fig 4B](#pone.0145514.g004){ref-type="fig"}).

![Nested regression models for all-cause mortality (A) and HF readmission (B).\
The incremental values of baseline LVEF, posttreatment LVEF, and LVEF change were assessed using 3 modeling steps. The first step consisted of fitting a multivariate base model of age, sex, HT, DM, IHD, COPD, ESRD, and NYHA Fc. Baseline LVEF, posttreatment LVEF, or LVEF change was included in the second step. The change in overall log likelihood ratio χ^2^ was used to assess the increase in predictive power after adding LVEF to base model.](pone.0145514.g004){#pone.0145514.g004}

Discussion {#sec012}
==========

To the best of our knowledge, this is the first report to directly compare the predictive values of baseline LVEF, posttreatment LVEF, and LVEF change for the long-term prognosis of patients with ADHF. This study yielded 3 major results. (1) Posttreatment LVEF was predictive for all-mortality and HF readmission, even after adjustment for age, sex, NYHA Fc, and comorbidities, but baseline LVEF was not. (2) The patients with improved LVEF \>10% had the most desirable prognosis, and LVEF change \>10% was predictive for all-mortality and HF readmission, even after adjustment for age, sex, NYHA Fc, and comorbidities. (3) Smaller LVEDD was associated with a higher probability of LVEF improvement 6 months after guideline-based HF therapy.

Baseline and Posttreatment LVEF {#sec013}
-------------------------------

Despite continual advances in HF therapeutics, declines in clinical condition necessitating hospitalization remain frequent. Common factors associated with deteriorating HF status include noncompliance with salt and fluid restriction directions, inappropriate drug therapy, infection, ischemia, and arrhythmias \[[@pone.0145514.ref019]\]. Critically ill patients with ADHF are often admitted to hospitals for emergency treatment, at which time baseline echocardiographic LVEF is typically assessed. However, the effects of medical history as well as lab and examination results obtained at HF patient admission are unclear because the clinical status of patients with ADHF fluctuates widely from the optimal condition. For instance, effective pharmacologic therapies block the activation of the renin-angiotensin system and adrenergic nervous system as well as halt or even reverse the progression of HF to improve clinical outcomes, whereas these improvements may not be present in nonadherent patients with HF. Our study showed that with optimal evidence-based HF therapy, LVEF could improve by up to 70% from baseline enrollment criteria of ≤35%. The difference indicated that using LVEF assessment irrespective of underlying condition may yield widely varying prognostic power; thus, we suggest that clinicians exercise caution in using baseline LVEF for guiding clinical decisions in managing these patients.

Reversible Dysfunction and Remodeling {#sec014}
-------------------------------------

In clinical practice, reverse remodeling describes the concept of recovery of myocardial dysfunction after mechanically unloading and restoring neurohormonal overactivation. Reverse remodeling, which is characterized by improved LVEF and reduced LV volume, may occur following myocardial revascularization, timely valve surgery, device therapy such as cardiac resynchronized therapy and ventricular assistance device therapy, and evidence-based medical treatment; it also occasionally occurs spontaneously. Depending on study population and HF etiology, 30%--70% of patients who receive optimal HF therapy exhibit improved LVEF. Crucially, reverse remodeling is closely correlated with long-term benefits in the morbidity and mortality of patients with HF \[[@pone.0145514.ref014],[@pone.0145514.ref020]--[@pone.0145514.ref023]\]. Therefore, myocardial remodeling, reflected by changes in LVEF and LV volumes in serial echocardiographic assessments, should be considered a practical prognosis indicator for risk stratification and should guide clinicians' management plans. For high-risk patients with pathologic remodeling after a reasonable observation period, intensive HF treatment including cardiac surgery or device implantation should be implemented.

In our study cohort of unselective heterogeneous patients with ADHF, approximately 40% of patients had a more than 10% improvement in LVEF 6 months posttreatment and demonstrated superior long-term prognosis in all-cause mortality and HF readmission compared with the groups with unchanged LVEF and a more than 10% decline in LVEF. Analysis using a cutoff value of 10% change of LVEF revealed a significant difference in prognosis between these groups, as shown in a Kaplan--Meier survival curve (*P* = .02). This suggested that some patients could have viable but dysfunctional myocardium. The aforementioned results are well supported by the results of previous clinical trials^11,16^ in which contrast-enhanced cardiac magnetic resonance was used to demonstrate that viable myocardium further predicted LV reverse remodeling. Therefore, LVEF assessed at least 6 months after the initiation of standard HF treatment was a more reliable prognosis predictor than baseline LVEF, which was poorly correlated with long-term outcomes.

LVEF improvement of more than 10% had greater predictive power than did posttreatment LVEF. Several observation studies on the predictive value of LVEF improvement in clinical practice reported different results. Wilcox et al \[[@pone.0145514.ref015]\] reported that the 4 clinical factors of female sex, no prior MI, nonischemic HF etiology, and no baseline digoxin use are associated with \>10% LVEF improvement in unselective patients with HF. Binkley et al \[[@pone.0145514.ref012]\] suggested that shorter QRS duration, female sex, nonischemic etiology of HF, absence of diabetes, and higher systolic blood pressure are associated with LVEF improvement in patients with dilated cardiomyopathy. Our results are consistent with reports from McNamara et al \[[@pone.0145514.ref013]\] and Matsumura et al \[[@pone.0145514.ref024]\], and smaller LVEDD measured at presentation was the strongest predictor of LVEF recovery 6 months posttreatment.

Effect of Comorbidities on Mortality and HF Readmission {#sec015}
-------------------------------------------------------

In addition to finding posttreatment LVEF and LVEF change to be crucial outcome predictors, this study revealed the comorbidities of advanced age, HT, DM, COPD, and ESRD to be associated with a higher risk of HF readmission, and advanced age, COPD, and ESRD to be associated with increased risk of all-cause mortality among hospitalized patients with HF. HF is increasingly prevalent among fragile elderly people, and more than one third of patients with HF have noncardiac comorbidities including stroke, DM, chronic kidney disease, and COPD in current HF registries \[[@pone.0145514.ref004]\]. These conditions contribute to the progression of HF pathologic remodeling through ongoing atherosclerosis processes with myocardial ischemia, refractory fluid overloading and neurohormonal activation, recurrent pulmonary infection, and episodic hypoxic events. It is associated with hospital readmission and overall mortality in patients with HF. In a population-based observation study \[[@pone.0145514.ref025]\], investigators found that advanced age, male sex, and the presence of comorbidities were associated with poorer survival among patients with HF. O'Connor and colleagues \[[@pone.0145514.ref026]\] performed posthoc analysis of an HF clinical trial and revealed that approximately half of all deaths and rehospitalization incidents within 60 days of HF hospitalization were secondary to comorbidities rather than deteriorating HF condition. Currently, in-hospital HF care mainly focuses on fluid status management and symptom relief. To reduce the readmission rate and improve survival, broader HF treatment strategies for the prevention and treatment of these comorbidities are required.

Clinical Implications {#sec016}
---------------------

Our results suggest that 40% of the patients experienced a significant improvement in LVEF with optimal therapy. LVEF assessed during admission with ADHF was not predictive of outcomes. However, posttreatment LVEF was a reliable prognostic tool and should guide the clinical management for these patients with HF. The strong association between LVEF change and clinical outcomes supports the incorporation of LVEF and LV measures after optimal medical treatment to facilitate the early identification of patients who have not responded to the treatment and who require further aggressive intervention to halt the progression of HF.

Limitations {#sec017}
-----------

Our study had some limitations. First, the data were confined to patients who survived more than 6 months after treatment and who received repeated LVEF assessments, which may limit the scope of our results. However, HF patient death in these 6 months may have mainly resulted from an inevitable clinical course, delayed diagnosis, or inadequate, inappropriate, or untimely treatment; thus, we believe that omitting these patients improved the validity of the data. This investigation focused on the predictability of LVEF after adequate HF therapy. Second, the study cohort was nonhomogenous, with variability in HF etiology, disease duration, and therapy. As with most observation studies, numerous possible uncontrolled confounding factors existed in this study; however, the results still provide new insights on the real-world clinical treatment of patients with HF. Further well-designed randomized studies are required to confirm the results of the present study. Finally, only severe systolic HF patients with LVEF ≤ 35% were enrolled, and whether the current findings may be generalized to patients with mildly impaired systolic function (LVEF 35%--50%) remains to be clarified.

Conclusions {#sec018}
===========

In this single-center cohort study, we found that posttreatment LVEF but not baseline LVEF was a powerful predictor of both all-cause mortality and HF readmission in patients with ADHF with severely depressed LVEF (≤35%). Improved LVEF (\>10% increase) 6 months posttreatment was associated with superior long-term prognosis, and baseline LVEDD was found to be a clinical marker predicting outcome. However, baseline LVEF did not predict cardiovascular outcomes and should not be used as a prognostic factor in clinical practice for patients with ADHF.
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